International Journal of Oral Science · 2024 · 21 citations · 36 references
Life SciencesCell BiologyOncologyCarcinogenesisMolecular OncologyNeoplasiaCancer GlycobiologyGlycan StructureGlycosylation PathwaysN-linked GlycosylationSquamous Cell CarcinomaAberrant Glycosylation In CancerFucosylation In CancerGlycosyltransferases In CancerN-glycan Core FucosylationN-glycosylation In CancerN-linked Glycan BiosynthesisProtein Glycosylation In OncogenesisTumor-associated Glycoproteins
Abstract SEMA7A belongs to the Semaphorin family and is involved in the oncogenesis and tumor progression. Aberrant glycosylation has been intricately linked with immune escape and tumor growth. SEMA7A is a highly glycosylated protein with five glycosylated sites. The underlying mechanisms of SEMA7A glycosylation and its contribution to immunosuppression and tumorigenesis are unclear. Here, we identify overexpression and aberrant N-glycosylation of SEMA7A in head and neck squamous cell carcinoma, and elucidate fucosyltransferase FUT8 catalyzes aberrant core fucosylation in SEMA7A at N-linked oligosaccharides (Asn 105, 157, 258, 330, and 602) via a direct protein‒protein interaction. A glycosylated statue of SEMA7A is necessary for its intra-cellular trafficking from the cytoplasm to the cytomembrane. Cytokine EGF triggers SEMA7A N-glycosylation through increasing the binding affinity of SEMA7A toward FUT8, whereas TGF-β1 promotes abnormal glycosylation of SEMA7A via induction of epithelial–mesenchymal transition. Aberrant N-glycosylation of SEMA7A leads to the differentiation of CD8 + T cells along a trajectory toward an exhausted state, thus shaping an immunosuppressive microenvironment and being resistant immunogenic cell death. Deglycosylation of SEMA7A significantly improves the clinical outcome of EGFR-targeted and anti-PD-L1-based immunotherapy. Finally, we also define RBM4, a splice regulator, as a downstream effector of glycosylated SEMA7A and a pivotal mediator of PD-L1 alternative splicing. These findings suggest that targeting FUT8-SEMA7A axis might be a promising strategy for improving antitumor responses in head and neck squamous cell carcinoma patients.
36
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia‐Wei Li, Seung-Oe Lim, Weiya Xia et al. · Nature Communications · 2016 · 1.1K citations · Full text
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia‐Wei Li, Seung-Oe Lim, Ezra M. Chung et al. · Cancer Cell · 2018 · 618 citations · Full text
Medicine, Cancer Biology, Oncology +12
Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin
Kazuhiro Suzuki, Tatsusada Okuno, Midori Yamamoto et al. · Nature · 2007 · 317 citations